This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to store the user consent for the cookies in the category "Necessary". This cookie is set by GDPR Cookie Consent plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics". The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting". These cookies do not store any personal information.Ĭookielawinfo-checkbox-advertising-targeting This category only includes cookies that ensures basic functionalities and security features of the website. Necessary cookies are absolutely essential for the website to function properly. While it’s important that physicians tailor their treatment approach for each patient, these data speak to the clinically important benefit that can be gained when adding ticagrelor to the current standard therapy in a patient population at increased risk for recurrent cardiovascular events in the long-term.” Marc Sabatine, MD, MPH, Chairman, Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women’s Hospital, Boston, MA, USA and lead investigator for PEGASUS-TIMI 54, said, “The PEGASUS-TIMI 54 trial demonstrated that the addition of ticagrelor to low-aspirin in patients with a prior heart attack significantly reduces the risk of dying from cardiovascular causes, having another heart attack, or having a stroke. PEGASUS TIMI-54 investigated ticagrelor tablets plus low-dose aspirin, compared to placebo plus low dose aspirin, for the long-term prevention of cardiovascular death, heart attack and stroke in patients who had experienced a heart attack one to three years prior to study enrollment. The approval of the expanded indication is based on the PEGASUS TIMI-54 study1, a large-scale outcomes trial involving more than 21,000 patients. Today’s approval is an important milestone that underscores the role Brilinta can play in reducing the risk of a subsequent cardiovascular event for patients both in the acute setting and in the longer term.” Brilinta plus aspirin was shown to significantly reduce the risk of having another heart attack After one year, patients with a history of heart attack can now be treated with 60mg twice daily.Įlisabeth Björk, Vice President, Head of Cardiovascular and Metabolic Diseases, Global Medicines Development, AstraZeneca, said, “We know that patients remain at risk beyond the first year after their heart attack. In the management of ACS, the recommended maintenance dose of Brilinta is 90mg twice daily during the first year after the ACS event. Brilinta also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS. For at least the first 12 months following ACS, it is superior to clopidogrel and is the first and only oral antiplatelet to demonstrate superior reductions in cardiovascular death. With this expanded indication, Brilinta is now approved to reduce the rate of cardiovascular death, myocardial infarction (MI, also known as heart attack) and stroke in patients with acute coronary syndrome (ACS) or a history of MI.īrilinta is an oral antiplatelet treatment that works by inhibiting platelet activation and was first approved by the FDA in July 2011 on the basis of data from the PLATO study. The US Food and Drug Administration (FDA) has approved AstraZeneca’s Brilinta® (ticagrelor) tablets at a new 60mg dose to be used in patients with a history of heart attack beyond the first year.
0 Comments
Leave a Reply. |